IP31-15 A PHASE 1 SAFETY, PK AND PRELIMINARY EFFICACY STUDY OF LOCALIZED THERAPY USING ENOLEN® (ENZALUTAMIDE) IMPLANTS FOR EARLY-STAGE PROSTATE CANCER | Journal of Urology
If the address matches an existing account you will receive an email with instructions to reset your password. If the address matches an existing account you will receive an email with instructions to retrieve your username More articles by this author More articles by this author More articles by this author More articles by this author More articles by this author More articles by this author More articles by this author More articles by this author More articles by this author More articles by this author Androgen Receptor Pathway Inhibitors (ARPI) have well established anti-cancer effects across multiple stages of prostate cancer (PCa). However, systemic anti-androgen therapy is associated with considerable side effects. We developed novel polymer-based enzalutamide containing implant, Enolen®, to provide continuous local drug administration to the prostate for men with localized PCa. NCT06257693 is a first in men Phase 1 trial to test the feasibility, safety, PK profile